Table 1.
Per-patient clinical outcomes and direct costs over 3 years
| Characteristics of incident patients diagnosed with HNSCC in the first semester of 2010 | N (%) | Death rate over 3 years, n (%) | Age at death, median (IQR) | Years-of-life lost, mean (SD) | Direct costs over 3 years, mean (SD) |
|---|---|---|---|---|---|
| All patients | 9,714 (100) | 4,456 (45.9) | 63 (56–75) | 10.9 (13.8) | 38,212 (33,924) |
| Gender | |||||
| Men | 7,614 (78.4) | 3,592 (47.2) | 63 (56–73) | 11.4 (13.9) | 39,537 (34,059) |
| Women | 2,100 (21.6) | 864 (41.1) | 68 (56–81) | 8.9 (13.3) | 33,412 (32,997) |
| Age at HNSCC diagnosis | |||||
| <65 years old | 6,008 (61.9) | 2,470 (41.1) | 57 (52–61) | 13.0 (16.0) | 41,909 (35,513) |
| 65+ years old | 3,706 (38.1) | 1,986 (53.6) | 76 (70–83) | 7.4 (7.9) | 32,221 (30,236) |
| HNSCC site at diagnosis | |||||
| Nasal cavity / paranasal sinuses | 497 (5.1) | 223 (44.9) | 75 (64–83) | 8.0 (11.7) | 30,711 (28,977) |
| Nasopharynx | 326 (3.4) | 137 (42.0) | 62 (53–73) | 10.9 (14.7) | 38,669 (26,532) |
| Lip | 380 (3.9) | 85 (22.4) | 83 (76–88) | 2.7 (6.7) | 10,129 (16,495) |
| Oral cavity | 2,035 (20.9) | 886 (43.5) | 64 (56–77) | 10.1 (13.7) | 36,883 (34,771) |
| Oropharynx | 2,819 (29.0) | 1,416 (50.2) | 61 (55–70) | 13.0 (14.6) | 41,589 (33,641) |
| Hypopharynx | 1,627 (16.8) | 888 (54.6) | 62 (55–72) | 13.6 (14.4) | 46,714 (35,402) |
| Larynx | 1,799 (18.5) | 676 (37.6) | 67 (58–78) | 8.0 (12.1) | 35,309 (33,524) |
| Ill-defined HNSCC | 231 (2.4) | 145 (62.8) | 64 (57–77) | 14.4 (14.4) | 33,143 (30,967) |
| Cancer stage at initial treatment | |||||
| Early | 2,978 (30.6) | 822 (27.6) | 75 (61–84) | 4.9 (9.8) | 19,819 (23,150) |
| Locally advanced | 5,856 (60.3) | 2,861 (48.9) | 62 (55–73) | 12.2 (14.3) | 46,791 (34,841) |
| Distant metastasis | 880 (9.1) | 773 (87.8) | 62 (55–71) | 22.4 (12.4) | 43,377 (33,953) |
| Charlson Comorbidity Index at initial treatment | |||||
| 0 | 4,241 (43.6) | 1,473 (34.7) | 61 (54–73) | 8.8 (13.7) | 32,706 (32,063) |
| 1 | 1,793 (18.5) | 784 (43.7) | 63 (57–75) | 10.2 (13.5) | 39,221 (34,419) |
| 2 | 1,722 (17.7) | 939 (54.5) | 63 (56–75) | 12.9 (14.1) | 42,875 (34,244) |
| ≥3 | 1,958 (20.2) | 1,260 (64.4) | 66 (58–77) | 14.2 (13.3) | 45,118 (35,145) |
Notes: Comparison of survival (log-rank test) and years-of-life lost or costs per patient (Kruskal–Wallis test) were statistically significant for all characteristics.
Abbreviations: HNSCC, head and neck squamous cell carcinoma.